Innovative technology from the Jagiellonian University launched for commercial use

Biocompatible nanocapsules allowing effective delivery of hydrophobic compounds to the body, developed at the Jagiellonian University, will soon be applied in pharmaceutical industry. The University sold the technology to the company CHDE Polska SA two years ago. The first products based on the invention are to become commercially available soon.

Biocompatible nanocapsules allowing effective delivery of hydrophobic compounds to the body, developed at the Jagiellonian University, will soon be applied in pharmaceutical industry. The University sold the technology to the company CHDE Polska SA two years ago. The first products based on the invention are to become commercially available soon.

The studies on creating biocompatible, highly stable polymeric nanocapsules that can efficiently encapsulate lipophilic active compounds and deliver them to the body continued for more than five years. The obtained solution will enable the production of stable and biocompatible capsules less than one micrometre in diameter, built of a polysaccharide coating and liquid oil core, whose stabilisation in the aqueous phase does not require using small molecule surfactants. The innovative solution was developed by Prof. Szczepan Zapotoczny from the JU Faculty of Chemistry and Dr Joanna Szafraniec-Szczęsny from the JU Faculty of Pharmacy. The results of their research were published in the prestigious journal Nanoscale.

As stressed by Prof. Zapotoczny, the technology worked out by the JU researchers may be applied in pharmacy, medicine, dietary supplementation, cosmetic, chemical and biotechnological industry as well as agriculture. Such a wide spectrum of potential uses is possible because the innovative capsules are easy to produce, universal and resistant to changing environmental parameters, which gives them advantage over many known nanostructural carriers of active substances.

In June 2018 the Jagiellonian University signed an agreement allowing the CHDE Polska S.A. to implement of the newly developed technology. The company, based in Rzeszów, has carried out tests proving the cost effectiveness of the solution, which allows to use it in dietary supplements produced on an industrial scale. These products are expected to become commercially available in 2021.

The CHDE Polska SA is a rapidly developing company selling high class medical devices used in diabetology and treatment of hypertension and lung diseases. The expertise combined with high product quality and dedication to patients’ well-being contribute to better health and quality of life of the patients suffering from these conditions.

 

source: Jagiellonian University website